NASDAQ : SERA

Sera Prognostics, Inc. — Company profile

Healthcare · Medical Devices · United States

Last price 2.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 80.48M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Details

NameSera Prognostics, Inc.
SectorHealthcare
IndustryMedical Devices
Employees72
Founded2008
Ipo Date2021-07-15
CeoZhenya Lindgardt
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price16.00
IsinUS81749D1072
Cusip81749D107
Cik1534969
Sic8071
Stock TypeCommon Stock
Share ClassClass A Shares

Key executives

NameTitle
Zhenya Lindgardt M.B.A.President, Chief Executive Officer and Director
Dr. John J. Boniface Ph.D.Chief Scientific Officer
Dr. Gregory C. Critchfield M.D., M.S.Executive Director
Dr. Paul Kearney Ph.D.Chief Data Officer
Scott GleasonChief Financial Officer and Treasurer
Robert G. HarrisonChief Information Officer
Jennifer ZibudaHead of Investor Relations
Benjamin G. Jackson J.D.General Counsel and Corporate Secretary
Austin AertsAdvisor
Lee AndersonChief Commercial Officer

Contact

Address2749 East Parleys Way, Suite 200, Salt Lake City, Utah 84109, United States
Phone801 990 0520
Websitehttps://www.sera.com